ArticleThe oncologist2026

Comparative real-world progression free survival of CDK4/6 inhibitors in HR+/HER2- breast cancer patients with bone metastases.

Roberta Scafetta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.